Full Program Just Released!
Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Sharsti Sandall

Sharsti Sandall

Executive Director, Oncology Research Pfizer

Seminars

Tuesday 13th October 2026

Leveraging Novel Payload MoAs & Combinations to Differentiate ADC Mechanisms & Combat Patient Resistance

Sharsti Sandall - Speaker at 17th World ADC San Diego Summit

View all Speakers

View Event Brochure